Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

RSS XML

Resultados 1 - 3 de 3

1 Próxima > >>

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.

Lévi, F A; Boige, V; Hebbar, M; Smith, D; Lepère, C; Focan, C; Karaboué, A; Guimbaud, R; Carvalho, C; Tumolo, S; Innominato, P; Ajavon, Y; Truant, S; Castaing, D; De Baere, T; Kunstlinger, F; Bouchahda, M; Afshar, M; Rougier, P; Adam, R; Ducreux, M.

Ann Oncol ; 27(2): 267-74, 2016 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-26578731

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.

Samalin, E; Afchain, P; Thézenas, S; Abbas, F; Romano, O; Guimbaud, R; Bécouarn, Y; Desseigne, F; Edeline, J; Mitry, E; Bouché, O; Adenis, A; Aparicio, T; Dorval, E; Kramar, A; Ychou, M.

Clin Res Hepatol Gastroenterol ; 35(1): 48-54, 2011 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-21634054

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.

Delord, J P; Pierga, J Y; Dieras, V; Bertheault-Cvitkovic, F; Turpin, F L; Lokiec, F; Lochon, I; Chatelut, E; Canal, P; Guimbaud, R; Mery-Mignard, D; Cornen, X; Mouri, Z; Bugat, R.

Br J Cancer ; 92(5): 820-6, 2005 Mar 14.

Artículo en Inglés | MEDLINE | ID: mdl-15756252

Resultados 1 - 3 de 3

1 Próxima > >>

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.